Navigation Links
Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
Date:12/10/2010

SAN ANTONIO Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900 patients with HER2-negative breast cancer treated with chemotherapy with or without bevacizumab.

"So far, no efficacy data from Phase III trials have been reported for early breast cancer. This will be the first," said von Minckwitz. "If the pathological complete response rate is higher with bevacizmab than without bevacizumab, it will provide a new option to improve neoadjuvant treatment in HER2-negative breast cancer."

Bevacizumab is currently approved in the United States in combination with paclitaxel for the first-line treatment of metastatic breast cancer. In July 2010, the Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12 to 1 to eliminate this indication from the treatment label of bevacizumab.

"A negative or positive result might have a significant effect on this picture," said von Minckwitz. "However, pathological response as a surrogate for outcome is only confirmed for chemotherapy. Long-term follow up, as well as results from adjuvant studies have to be awaited."

The researchers investigated whether adding bevacizumab to treatment with four cycles of epirubicin/cyclophosphomide, followed by four cycles of docetaxel improved the rate of pathological complete response, which was defined as no invasive or non-invasive residual cancer in the breast or nodes.

Between May 2007 and June 2010, 944 patients were assigned chemotherapy treatment with epirubicin/cyclophosphamide followed by docetaxel; 945 patients were assigned this treatment plus bevacizumab.

After the first four cycles, the researchers performed an interim assessment; 24 percent of patients treated without bevacizumab and 17 percent of patients treated with bevacizumab showed no response and were discontinued from treatment.

Interim safety data from the trial, published earlier this year, indicated that treatment with bevacizumab was feasible. Patients assigned bevacizumab experienced more leukopenia, infections, mucositis and hypertension, but less edema. This safety profile is no different from that reported in first-line metastatic trials or Phase II adjuvant trials of bevacizumab, according to von Minckwitz.

Full results on the histological response and surgical outcome will be reported during the symposium.

"The results will provide an important signal as to whether bevacizumab will be effective as an adjuvant treatment," said von Minckwitz.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: